Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 17, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Tracey L. McCain , Esq. to its Board of Directors.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 16, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the appointment of Kristen Harrington-Smith as ImmunoGen’s Senior Vice President
View HTML
Toggle Summary ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 16, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer.
View HTML
Toggle Summary ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
Triplet Demonstrated Manageable Safety Profile and Encouraging Activity, with 55% Objective Response Rate Across All Doses/Schedules in Escalation Data for IMGN632 in Frontline BPDCN Patients Will Also be Presented WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 4, 2021-- ImmunoGen Inc.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 29, 2021 the compensation committee of the Company’s Board of Directors granted a
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
Top-Line Data from Pivotal SORAYA Trial Evaluating Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer on Track for Release this Quarter IMGN632 AML Combination Data to be Highlighted at ASH Annual Meeting PICCOLO, Single-Arm Study of Mirvetuximab in Platinum-Sensitive Ovarian Cancer,
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 14, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2021 the compensation committee of the Company’s Board of Directors granted
View HTML
Toggle Summary ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 22, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray , MD, FAAP to its Board of Directors.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
View HTML